Dataset Information

Transcriptomic profiling of SGLT2 inhibitor-treated hypertensive rats

ABSTRACT: Background: Sodium-glucose co-transporter-2 inhibitor (SGLT2i) compounds are antihyperglycemic medications that may improve cardiovascular disease (CVD) and chronic kidney disease prognosis in patients with diabetes mellitus. Methods: We conducted a detailed RNA-sequencing-based exploration of transcriptomic changes in response to empaglifozin in eight different tissuesfrom a rat model of spontaneous hypertension. Corresponding computational analyses were performed to analyze these data. Results: We discovered that empaglifozin exerts potent transcriptomic effects upon various tissues. Empaglifozin therapy may exert effects upon the kidney by impacting aldosterone-regulated sodium resorption, lyosome. The functional enrichment of DEGs indicated empaglifozin may regulate blood pressure, blood glucose, lipid homeostasis and nervous system in SHR. Consistent with our RNA-Seq findings, following 1-month empaglifozin administration, immunofluorescence staining revealed enhanced renal expression of caveolin-1. Conclusions: These findings offer value as a foundation guiding further exploration regarding the effects associated with SGLT2i therapy in the context of hypertension.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE206986 | GEO | 2023/09/06

REPOSITORIES: GEO

ACCESS DATA

Similar Datasets

Project description:Background: Inhibitors of sodium glucose linked transporter 2 (SGLT2i) improve heart failure (HF) outcomes in patients independent of diabetes. While animal studies suggest SGLT2i improve cardiac metabolism, the effect of SGLT2i on mitochondrial function in the heart is not known. Our goal was to assess the effects of SGLT2i on mitochondrial function, high energy phosphates and genes encoding mitochondrial proteins in hearts of mice with and without diet-induced diabetes. Methods & Results: Ertugliflozin (Ertu; formulated to 0.5 mg/g of diet) was given for 4 months to mice fed a high fat, high sucrose (HFHS) diet that causes diabetic cardiomyopathy or control diet (CD). Mitochondrial function was measured in isolated cardiac mitochondria. Myocardial energetics were assessed by NMR spectroscopy simultaneously with systolic function in isolated beating hearts. Myocardial gene expression was assessed by RNA seq using gene set enrichment analysis. HFHS diet caused myocardial hypertrophy and diastolic dysfunction, mitochondrial dysfunction (decreased ATP production, increased reactive oxygen species release) and an impaired energetic response to increased work demand - all of which were prevented by Ertu. Conctractile function, as reflected by the rate x pressure product (RPP), was super-normalized to a value 124% of CD hearts at high work demand. In control mice, Ertu had no effect on isolated mitochondria function or high energy phosphates, but similar to HFHS hearts, caused super-normalization of RPP to 125% of CD hearts. By GSEA the highest scoring gene set for Ertu treatment was oxidative phosphorylation (OXPHOS), which was up-regulated across all groups while controlling for diet with a Normalized Enrichment Score (NES) of +3.71, and was similarly up-regulated in HFHS-fed mice (NES, +3.32) and in CD-fed mice (NES, +3.34). Fatty acid metabolism (FAM) was the second-highest scoring gene set for Ertu, and, like OXPHOS, was up-regulated independent of diet (NES, +2.82). Conclusion: The super-normalization of contractile function and induction of the OXPHOS and FAM gene sets by Ertu are independent of diabetic status. Pro-metabolic remodeling of the myocardium by Ertu may support increased contractile function and contribute to the beneficial actions of Ertu in states such as heart failure that are associated with impaired cardiac mitochondrial function.

Dataset Information

Transcriptomic profiling of SGLT2 inhibitor-treated hypertensive rats

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure